Understand the source comparison
Adamax Contraindications: Drug Interaction Comparison
Insulin (basal or bolus) Additive glucose-lowering; GLP-1 enhances insulin secretion while exogenous insulin independently lowers glucose High. Hypoglycemia incidence 15–20% without dose adjustment Reduce insulin dose by 20–30% at Adamax initiation; implement
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Insulin (basal or bolus)
- Additive glucose-lowering; GLP-1 enhances insulin secretion while exogenous insulin independently lowers glucose
- High. Hypoglycemia incidence 15–20% without dose adjustment
- Reduce insulin dose by 20–30% at Adamax initiation; implement continuous glucose monitoring; set hypoglycemia threshold at 70 mg/dL
- Sulfonylureas (glipizide, glyburide)
- Non-glucose-dependent insulin secretion combined with GLP-1-mediated enhancement creates severe hypoglycemia risk
- Very High. Hypoglycemia incidence 25–35%
- Discontinue sulfonylurea and transition to metformin or SGLT2 inhibitor before Adamax initiation; if discontinuation not possible, exclude from protocol
- Oral contraceptives
- Delayed gastric emptying reduces oral contraceptive absorption by 20–40%, decreasing contraceptive efficacy
- Moderate
- Administer oral contraceptive at least one hour before Adamax injection; consider transition to non-oral contraception (IUD, implant, transdermal)
- Warfarin
- Altered gastric emptying changes warfarin absorption kinetics; GLP-1 agonists may increase INR variability
- Increase INR monitoring frequency to weekly during titration; expect potential need for warfarin dose reduction of 10–15%
- Levothyroxine
- Delayed gastric emptying reduces levothyroxine absorption; TSH elevation documented in 8–12% of patients on GLP-1 therapy
- Separate levothyroxine administration by at least four hours from Adamax injection; re-measure TSH at 6–8 weeks and adjust dose if needed